Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Tunggal Idaman Abdi
East Jakarta, Jakarta, Indonesiatunggal-pharma.com ↗
- Ownership
- Private
- Employees
- ~750
- Development stage
- Other
01
Overview
PT Tunggal Idaman Abdi is a leading Indonesian pharmaceutical manufacturer specializing in injectable contraceptives (notably Triclofem – depot medroxyprogesterone acetate), which received WHO Prequalification in 2021. The company supplies both private and public sectors, maintains strategic alliances, and has expanded market presence in Indonesia and low- and middle-income countries.[2][4][6][8][10]
- Therapeutic areas
- Women's Health
- Modalities
- Small moleculeHormoneBiologic
- Industry
- Biotech
02
Partnerships
Concept FoundationUNFPAHealth Concepts International
Beyond the preview
Go deeper on Tunggal Idaman Abdi.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tunggal Idaman Abdi.